Chimeric’s CEO and managing director, Jennifer Chow, said, “We are delighted with USPTO’s decision to grant patent protection for our CORE-NK platform in the United States, the single largest global market for biopharmaceutical products."
Chimeric secures US patent for its CHM 0201 cell therapy platform technology
April 8, 2024 Australian Biotech
Latest Video
New Stories
-
BCAL advances early cancer detection portfolio as Australian launch looms
November 19, 2025 - - Australian Biotech -
Minister managing the 'double-whammy' of participant and plan growth
November 19, 2025 - - Latest News -
Is this disconnect so entrenched we can no longer recognise the presence of a problem?
November 19, 2025 - - Latest News -
Tryp advances psilocin trial for binge eating disorder as second patient enrolled
November 18, 2025 - - Australian Biotech -
Nyrada advances toward Phase 2a trial of cardioprotective candidate
November 18, 2025 - - Australian Biotech -
We know they're planning something on these issues, because they told us
November 18, 2025 - - Latest News -
The need to honour a strong history while ensuring the future is guided by the 'good guys'
November 17, 2025 - - Latest News